_id
691052efccc777a4e85d54f4
Ticker
COLL
Name
Collegium Pharmaceutical Inc
Exchange
NASDAQ
Address
100 Technology Center Drive, Stoughton, MA, United States, 02072
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.collegiumpharma.com
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Last Close
48.36
Volume
267309
Current Price
47.88
Change
-0.9925558312655023
Last Updated
2025-11-29T11:44:37.030Z
Image
data:image/webp;base64,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
Ipo Date
2015-05-07T00:00:00.000Z
Market Cap
1475600384
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9758833333333333
Sentiment Sources
18
Rating
4.2
Target Price
46.8
Strong Buy
2
Buy
2
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
209361000
Cost Of Revenue
80190000
Gross Profit
129171000
Operating Expenses
65551000
Operating Income
63620000
Interest Expense
21767000
Pretax Income
43436000
Net Income
31507000
Eps
0.7988612544304764
Dividends Per Share
-
Shares Outstanding
31610976
Income Tax Expense
11929000
EBITDA
121709000
Operating Margin
30.38770353599763
Total Other Income Expense Net
-20184000
Cash
169946000
Short Term Investments
135767000
Receivables
233949000
Inventories
38052000
Total Current Assets
613870000
Property Plant Equipment
16681000
Total Assets
1607328000
Payables
7647000
Short Term Debt
65955000
Long Term Debt
743533000
Total Liabilities
1332520000
Equity
274808000
Depreciation
56506000
Change In Working Capital
-8503000
Cash From Operations
78438000
Capital Expenditures
188000
Cash From Investing
-30868000
Cash From Financing
-14818000
Net Change In Cash
32748000
PE
28.638
PB
6.871641048295538
ROE
11.465095630403772
ROA
1.9602097393935776
FCF
78250000
Fcf Percent
0.37375633475193565
Piotroski FScore
4
Health Score
54
Deep Value Investing Score
4.5
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
7.8
Garp Investing Score
6.5
Growth Investing Score
6
Momentum Investing Score
6.5
Net Net Investing Score
2.5
Quality Investing Score
6
Value Investing Score
4
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
209361000
Quarters > 0 > income Statement > cost Of Revenue
80190000
Quarters > 0 > income Statement > gross Profit
129171000
Quarters > 0 > income Statement > operating Expenses
65551000
Quarters > 0 > income Statement > operating Income
63620000
Quarters > 0 > income Statement > interest Expense
21767000
Quarters > 0 > income Statement > pretax Income
43436000
Quarters > 0 > income Statement > net Income
31507000
Quarters > 0 > income Statement > eps
0.7988612544304764
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
39439890
Quarters > 0 > income Statement > income Tax Expense
11929000
Quarters > 0 > income Statement > EBITDA
121709000
Quarters > 0 > income Statement > operating Margin
30.38770353599763
Quarters > 0 > income Statement > total Other Income Expense Net
-20184000
Quarters > 0 > balance Sheet > cash
169946000
Quarters > 0 > balance Sheet > short Term Investments
135767000
Quarters > 0 > balance Sheet > receivables
233949000
Quarters > 0 > balance Sheet > inventories
38052000
Quarters > 0 > balance Sheet > total Current Assets
613870000
Quarters > 0 > balance Sheet > property Plant Equipment
16681000
Quarters > 0 > balance Sheet > total Assets
1607328000
Quarters > 0 > balance Sheet > payables
7647000
Quarters > 0 > balance Sheet > short Term Debt
65955000
Quarters > 0 > balance Sheet > long Term Debt
743533000
Quarters > 0 > balance Sheet > total Liabilities
1332520000
Quarters > 0 > balance Sheet > equity
274808000
Quarters > 0 > cash Flow > net Income
31507000
Quarters > 0 > cash Flow > depreciation
56506000
Quarters > 0 > cash Flow > change In Working Capital
-8503000
Quarters > 0 > cash Flow > cash From Operations
78438000
Quarters > 0 > cash Flow > capital Expenditures
188000
Quarters > 0 > cash Flow > cash From Investing
-30868000
Quarters > 0 > cash Flow > cash From Financing
-14818000
Quarters > 0 > cash Flow > net Change In Cash
32748000
Quarters > 0 > ratios > PE
0.7988612544304764
Quarters > 0 > ratios > PB
6.871641048295538
Quarters > 0 > ratios > ROE
11.465095630403772
Quarters > 0 > ratios > ROA
1.9602097393935776
Quarters > 0 > ratios > FCF
78250000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.37375633475193565
Quarters > 0 > health Score
54
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
188000000
Quarters > 1 > income Statement > cost Of Revenue
79616000
Quarters > 1 > income Statement > gross Profit
108384000
Quarters > 1 > income Statement > operating Expenses
73279000
Quarters > 1 > income Statement > operating Income
35105000
Quarters > 1 > income Statement > interest Expense
20463000
Quarters > 1 > income Statement > pretax Income
17025000
Quarters > 1 > income Statement > net Income
11983000
Quarters > 1 > income Statement > eps
0.30666114951278034
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
39075703
Quarters > 1 > income Statement > income Tax Expense
5042000
Quarters > 1 > income Statement > EBITDA
94096000
Quarters > 1 > income Statement > operating Margin
18.67287234042553
Quarters > 1 > income Statement > total Other Income Expense Net
-18080000
Quarters > 1 > balance Sheet > cash
117348000
Quarters > 1 > balance Sheet > short Term Investments
104805000
Quarters > 1 > balance Sheet > receivables
213023000
Quarters > 1 > balance Sheet > inventories
38148000
Quarters > 1 > balance Sheet > total Current Assets
549211000
Quarters > 1 > balance Sheet > property Plant Equipment
18166000
Quarters > 1 > balance Sheet > total Assets
1592631000
Quarters > 1 > balance Sheet > payables
10890000
Quarters > 1 > balance Sheet > short Term Debt
65921000
Quarters > 1 > balance Sheet > long Term Debt
758336000
Quarters > 1 > balance Sheet > total Liabilities
1360425000
Quarters > 1 > balance Sheet > equity
232206000
Quarters > 1 > cash Flow > net Income
11983000
Quarters > 1 > cash Flow > depreciation
56608000
Quarters > 1 > cash Flow > change In Working Capital
-5864000
Quarters > 1 > cash Flow > cash From Operations
72439000
Quarters > 1 > cash Flow > capital Expenditures
65000
Quarters > 1 > cash Flow > cash From Investing
-2915000
Quarters > 1 > cash Flow > cash From Financing
-48370000
Quarters > 1 > cash Flow > net Change In Cash
21154000
Quarters > 1 > ratios > PE
0.30666114951278034
Quarters > 1 > ratios > PB
8.05726234309191
Quarters > 1 > ratios > ROE
5.160504035210115
Quarters > 1 > ratios > ROA
0.7524027850770203
Quarters > 1 > ratios > FCF
72374000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.384968085106383
Quarters > 1 > health Score
48
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
177757000
Quarters > 2 > income Statement > cost Of Revenue
80433000
Quarters > 2 > income Statement > gross Profit
97324000
Quarters > 2 > income Statement > operating Expenses
75637000
Quarters > 2 > income Statement > operating Income
21687000
Quarters > 2 > income Statement > interest Expense
20790000
Quarters > 2 > income Statement > pretax Income
3122000
Quarters > 2 > income Statement > net Income
2417000
Quarters > 2 > income Statement > eps
0.07359892629002063
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
32840153
Quarters > 2 > income Statement > income Tax Expense
705000
Quarters > 2 > income Statement > EBITDA
80476000
Quarters > 2 > income Statement > operating Margin
12.200363417474417
Quarters > 2 > income Statement > total Other Income Expense Net
-18565000
Quarters > 2 > balance Sheet > cash
96192000
Quarters > 2 > balance Sheet > short Term Investments
101582000
Quarters > 2 > balance Sheet > receivables
228710000
Quarters > 2 > balance Sheet > inventories
37218000
Quarters > 2 > balance Sheet > total Current Assets
527553000
Quarters > 2 > balance Sheet > property Plant Equipment
19395000
Quarters > 2 > balance Sheet > total Assets
1631388000
Quarters > 2 > balance Sheet > payables
17853000
Quarters > 2 > balance Sheet > short Term Debt
65887000
Quarters > 2 > balance Sheet > long Term Debt
773127000
Quarters > 2 > balance Sheet > total Liabilities
1396954000
Quarters > 2 > balance Sheet > equity
234434000
Quarters > 2 > cash Flow > net Income
2417000
Quarters > 2 > cash Flow > depreciation
56564000
Quarters > 2 > cash Flow > change In Working Capital
-15704000
Quarters > 2 > cash Flow > cash From Operations
55398000
Quarters > 2 > cash Flow > capital Expenditures
798000
Quarters > 2 > cash Flow > cash From Investing
-9680000
Quarters > 2 > cash Flow > cash From Financing
-25236000
Quarters > 2 > cash Flow > net Change In Cash
20482000
Quarters > 2 > ratios > PE
0.07359892629002063
Quarters > 2 > ratios > PB
6.707160760128651
Quarters > 2 > ratios > ROE
1.0309937978279602
Quarters > 2 > ratios > ROA
0.14815604871434632
Quarters > 2 > ratios > FCF
54600000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.30716089943012087
Quarters > 2 > health Score
44
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
181949000
Quarters > 3 > income Statement > cost Of Revenue
83661000
Quarters > 3 > income Statement > gross Profit
98288000
Quarters > 3 > income Statement > operating Expenses
60177000
Quarters > 3 > income Statement > operating Income
38111000
Quarters > 3 > income Statement > interest Expense
22654000
Quarters > 3 > income Statement > pretax Income
17269000
Quarters > 3 > income Statement > net Income
12536000
Quarters > 3 > income Statement > eps
0.31254324863326527
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
40109649
Quarters > 3 > income Statement > income Tax Expense
4733000
Quarters > 3 > income Statement > EBITDA
96435000
Quarters > 3 > income Statement > operating Margin
20.945979367844835
Quarters > 3 > income Statement > total Other Income Expense Net
-20842000
Quarters > 3 > balance Sheet > cash
70565000
Quarters > 3 > balance Sheet > short Term Investments
92198000
Quarters > 3 > balance Sheet > receivables
228540000
Quarters > 3 > balance Sheet > inventories
35560000
Quarters > 3 > balance Sheet > total Current Assets
482257000
Quarters > 3 > balance Sheet > property Plant Equipment
20151000
Quarters > 3 > balance Sheet > total Assets
1663591000
Quarters > 3 > balance Sheet > payables
3934000
Quarters > 3 > balance Sheet > short Term Debt
65854000
Quarters > 3 > balance Sheet > long Term Debt
787905000
Quarters > 3 > balance Sheet > total Liabilities
1434749000
Quarters > 3 > balance Sheet > equity
228842000
Quarters > 3 > cash Flow > net Income
12536000
Quarters > 3 > cash Flow > depreciation
56512000
Quarters > 3 > cash Flow > change In Working Capital
16809000
Quarters > 3 > cash Flow > cash From Operations
84644000
Quarters > 3 > cash Flow > capital Expenditures
570000
Quarters > 3 > cash Flow > cash From Investing
-11762000
Quarters > 3 > cash Flow > cash From Financing
-41277000
Quarters > 3 > cash Flow > net Change In Cash
31605000
Quarters > 3 > ratios > PE
0.31254324863326527
Quarters > 3 > ratios > PB
8.39203465325421
Quarters > 3 > ratios > ROE
5.478015399271112
Quarters > 3 > ratios > ROA
0.7535506022814502
Quarters > 3 > ratios > FCF
84074000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.462074537370362
Quarters > 3 > health Score
48
Valuation > metrics > PE
28.638
Valuation > metrics > PB
6.871641048295538
Valuation > final Score
15.6344
Valuation > verdict
71.8% Overvalued
Profitability > metrics > ROE
11.465095630403772
Profitability > metrics > ROA
5.132519914639907
Profitability > metrics > Net Margin
0.15049125672880814
Profitability > final Score
61
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
4.848912695409158
Risk > metrics > Interest Coverage
2.9227730050075804
Risk > final Score
18
Risk > verdict
High
Liquidity > metrics > Current Ratio
8.340398358740252
Liquidity > metrics > Quick Ratio
7.823401538001685
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
40
Prev Valuations > 1
40
Prev Valuations > 2
40
Prev Profitabilities > 0
26
Prev Profitabilities > 1
5
Prev Profitabilities > 2
29
Prev Risks > 0
13
Prev Risks > 1
10
Prev Risks > 2
13
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:33:05.739Z
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACollegium Pharmaceutical (NASDAQ:COLL) Earns Overweight Rating from Analysts at Barclays Defense World
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$46.8
Analyst Picks
Strong Buy
2
Buy
2
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Medium
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 130.78% of the total shares of Collegium Pharmaceutical Inc
1.
BlackRock Inc(16.9571%)
since
2025/06/30
2.
Rubric Capital Management LP(10.0239%)
since
2025/06/30
3.
Eventide Asset Management, LLC(8.3848%)
since
2025/06/30
4.
Vanguard Group Inc(7.1367%)
since
2025/06/30
5.
iShares Core S&P Small-Cap ETF(6.0684%)
since
2025/08/31
6.
Amvescap Plc.(5.031%)
since
2025/06/30
7.
Renaissance Technologies Corp(4.8288%)
since
2025/06/30
8.
Principal Financial Group Inc(4.6564%)
since
2025/06/30
9.
Fuller & Thaler Asset Management Inc(4.5426%)
since
2025/06/30
10.
FullerThaler Behavioral Small-Cap Equity(4.3388%)
since
2025/06/30
11.
FullerThaler Behavioral Sm-Cp Eq R6(4.3388%)
since
2025/06/30
12.
State Street Corp(4.2994%)
since
2025/06/30
13.
Eventide Gilead N(4.2676%)
since
2025/06/30
14.
Eventide Healthcare & Life Sciences I(4.0798%)
since
2025/06/30
15.
Vanguard Total Stock Mkt Idx Inv(3.0408%)
since
2025/07/31
16.
Dimensional Fund Advisors, Inc.(2.7338%)
since
2025/06/30
17.
Emerald Advisers, LLC(2.6587%)
since
2025/06/30
18.
Massachusetts Financial Services Company(2.5369%)
since
2025/06/30
19.
Geode Capital Management, LLC(2.4768%)
since
2025/06/30
20.
iShares Russell 2000 ETF(2.4559%)
since
2025/08/31
21.
Morgan Stanley - Brokerage Accounts(1.9485%)
since
2025/06/30
22.
Principal SmallCap R5(1.7519%)
since
2025/07/31
23.
Principal U.S. Small Cap Equity(1.7519%)
since
2025/06/30
24.
Emerald Mutual Fund Advisers Trust(1.7479%)
since
2025/06/30
25.
MFS New Discovery I(1.7108%)
since
2025/07/31
26.
Bank of America Corp(1.6342%)
since
2025/06/30
27.
Victory Capital Management Inc.(1.615%)
since
2025/06/30
28.
HHG PLC(1.4905%)
since
2025/06/30
29.
Invesco Main Street Small Cap R6(1.4185%)
since
2025/07/31
30.
Invesco Small Cap Core(1.3945%)
since
2025/06/30
31.
Janus Henderson Hrzn Glb SC E2 USD(1.2777%)
since
2025/07/31
32.
Charles Schwab Investment Management Inc(1.2256%)
since
2025/06/30
33.
Northern Trust Corp(1.2088%)
since
2025/06/30
34.
Vanguard Institutional Extnd Mkt Idx Tr(1.0909%)
since
2025/07/31
35.
Fidelity Small Cap Index(1.0187%)
since
2025/06/30
36.
Pacer US Small Cap Cash Cows 100 ETF(0.9636%)
since
2025/08/29
37.
SPDR® Portfolio S&P 600™ Sm Cap ETF(0.904%)
since
2025/08/29
38.
iShares Russell 2000 Growth ETF(0.8937%)
since
2025/08/31
39.
iShares S&P Small-Cap 600 Growth ETF(0.8783%)
since
2025/08/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.